# A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

> **NCT03698864** · PHASE2 · COMPLETED · sponsor: **Processa Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Necrobiosis Lipoidica

## Interventions

- **DRUG:** PCS499

## Key facts

- **NCT ID:** NCT03698864
- **Lead sponsor:** Processa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698864, "A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03698864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*